Optimal dose of intrathecal hyperbaric bupivacaine with opioids for cesarean delivery:a prospective, randomized, double-blinded, dose-ranging study
Not Applicable
- Conditions
- Cesarean delivery
- Registration Number
- JPRN-UMIN000023692
- Lead Sponsor
- Tohoku Kosai Hospital, Department of Anesthesiology
- Brief Summary
The ED95 for success (main) was 12.6mg. The incidence of respiratory discomfort and maternal satisfaction scores did not differ significantly between dose groups. Phenylephrine dose and nausea/vomiting incidence increased with increasing doses of bupivacaine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1. active labor 2. ruptured membranes 3. three or more previous Cesarean deliveries 4. gestational diabetes 5. pregnancy induced hypertension 6. intrauterine growth retardation 7. placenta previa 8. body mass index more than 35
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the optimal dose of hyperbaric bupivacaine co-administered with fentanyl and morphine for Cesarean delivery without supplemental analgesia
- Secondary Outcome Measures
Name Time Method 1. the cumulative dose of phenylephrine 2. frequency of adverse events 3. maternal satisfaction